Relmada, reeling from 2 late-phase flops, plots comeback for depression drug

Relmada Therapeutics is preparing for one last roll of the dice. After blaming the failure of its first two phase 3 trials on an “unplausible placebo response,” the depression drug developer has sifted through the ashes of the flameouts and outlined plans to start a new study.